Bradley Palmer, DO
Internal Medicine · Overland Park, KSNPI 1982635207
Payments from drug & device makers
Across 226 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1000
- AstraZeneca$775
- Pfizer$384
- Novo Nordisk$302
- Bayer$229
- Lilly USA, LLC$224
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,150100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $1,000 |
| AstraZeneca | 30 | $775 |
| Pfizer | 25 | $384 |
| Novo Nordisk | 19 | $302 |
| Bayer | 12 | $229 |
| Lilly USA, LLC | 11 | $224 |
| Abbott | 9 | $158 |
| GSK | 10 | $157 |
| Amgen | 6 | $93 |
| Antares Pharma, Inc. | 5 | $86 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Novartis | 4 | $59 |
| Boehringer Ingelheim | 3 | $54 |
| Ardelyx, Inc. | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| IBSA Pharma Inc. | 2 | $41 |
| Shield Therapeutics Inc | 1 | $37 |
| Johnson & Johnson | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Procept Biorobotics Corporation | 1 | $20 |
| Exeltis, USA Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
| Endogastric Solutions, Inc | 2 | $9 |
How this compares
$4,150 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $89,894 |
| FarxigaDapagliflozin Propanediol | 43 | $37,060 |
| JardianceEmpagliflozin | 25 | $36,016 |
| OzempicSemaglutide | 31 | $30,571 |
| JanuviaSitagliptin Phosphate | 28 | $24,306 |
| MounjaroTirzepatide | 20 | $22,451 |
| XareltoRivaroxaban | 13 | $20,326 |
| TrulicityDulaglutide | 11 | $12,516 |
| TrintellixVortioxetine Hydrobromide | 13 | $9,642 |
| SynthroidLevothyroxine Sodium | 70 | $8,290 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $8,217 |
| KerendiaFinerenone | 11 | $6,893 |
| Atorvastatin Calcium | 550 | $4,876 |
| Rosuvastatin Calcium | 337 | $4,470 |
| VascepaIcosapent Ethyl | 12 | $4,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $384 | $89,89481 claims |
| AstraZenecaFarxiga | $775 | $37,06043 claims |
| Boehringer IngelheimJardiance | $54 | $36,01625 claims |
| Lilly USA, LLCMounjaro, Trulicity | $224 | $34,96631 claims |
| Novo NordiskOzempic | $302 | $30,57131 claims |
| Johnson & JohnsonXarelto | $33 | $20,32613 claims |
| AbbVieSynthroid | $1,000 | $8,29070 claims |
| BayerKerendia | $229 | $6,89311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Overland Park
- Jonathan JacobsOverland Park$827K
- Thomas CuevasOverland Park$382K
- Lisa VansaghiOverland Park$131K
- Herbert WaxmanOverland Park$82K
- Shadrach SmithOverland Park$27K
- David EdalatiOverland Park$21K
- Jennifer BrownOverland Park$9K
- Ammar KhalifaOverland Park$8K
- Bruce SalvaggioOverland Park$8K
- Vijaya SamuelOverland Park$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.